Vaisala delivered strong topline and solid order growth in Q1.
Redeye updates its estimates of Carasent after the Q1 2023 report, change of focus, and cost-savings...
Redeye thinks the Q1 report was strong and lays a solid foundation for Sivers possibility of reachin...
Redeye updates on Better Collective ahead of its Q1-results (due 16 May) where we expect continued s...
Redeye updates its estimates following Arise’s Q1 report.
Redeye concludes that Railcare had a promising start to the year with higher sales and earnings than...
Vow will publish its Q1 update on 9 May (the company reports semi-annually).
Netcompany had a solid start to 2023, including a 3% beat to company-compiled EBITDA consensus.
Redeye retains its positive view of CombinedX following a strong Q1 both in terms of growth and marg...
Redeye retains its positive view of Transtema following a soft Q1 hurt by a harsh Norwegian winter.
We expect 27% y-o-y Q1 ARR growth; likely reiterating guidance Slightly altering our view on the gro...
Redeye endorses the green light to start the experimental phase of the FDA dissolution research proj...
VibroSense redovisade en nettoomsättning om 0,48 MSEK, vilket är en ökning med 45,6 % y-o-y.
Redeye provides an update in relation to Optomed’s Q1 2023 report.
EBITDA SEK 76m vs. ABGSCe 60m Hedges positively impacting own production The share is trading at 11x...
Redeye provides an update following the Q1’23 report from Coala Life.
Hanza inleder 2023 på bästa vis med 23% organisk tillväxt och en marginal som redan nosar på 2025 år...
12,5% organisk tillväxt… Marknaden är förvånansvärt stark och den organiska tillväxten var 12,5% i Q...
Q1-resultatet var svagt som förväntat Nettoomsättningen sjönk med 21% till 715 mkr (910) och EBIT bl...
Stark Q1’23 med stort bidrag från Production Arise rapporterade ett starkt Q1’23.
